FDMT vs. CVAC, ABCL, AVBP, COGT, PAHC, RLAY, CDMO, SANA, TYRA, and SEPN
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include CureVac (CVAC), AbCellera Biologics (ABCL), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Tyra Biosciences (TYRA), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics vs.
4D Molecular Therapeutics (NASDAQ:FDMT) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.
4D Molecular Therapeutics has higher earnings, but lower revenue than CureVac. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics received 25 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 69.44% of users gave 4D Molecular Therapeutics an outperform vote while only 54.35% of users gave CureVac an outperform vote.
4D Molecular Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.5, suggesting that its stock price is 150% more volatile than the S&P 500.
4D Molecular Therapeutics currently has a consensus target price of $38.56, suggesting a potential upside of 741.82%. CureVac has a consensus target price of $10.00, suggesting a potential upside of 143.90%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe 4D Molecular Therapeutics is more favorable than CureVac.
CureVac has a net margin of 20.72% compared to 4D Molecular Therapeutics' net margin of 0.00%. CureVac's return on equity of 21.98% beat 4D Molecular Therapeutics' return on equity.
In the previous week, 4D Molecular Therapeutics had 24 more articles in the media than CureVac. MarketBeat recorded 25 mentions for 4D Molecular Therapeutics and 1 mentions for CureVac. CureVac's average media sentiment score of 0.59 beat 4D Molecular Therapeutics' score of 0.37 indicating that CureVac is being referred to more favorably in the news media.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 7.3% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
4D Molecular Therapeutics beats CureVac on 10 of the 18 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FDMT) was last updated on 1/17/2025 by MarketBeat.com Staff
Free FDMT Stock Alerts